roxadustat

12/16/2022 - "After applying Roxadustat, the patient's anemia improved significantly. "
05/26/2021 - "After applying Roxadustat, the patient's anemia improved significantly. "
10/01/2023 - "Roxadustat was effective in maintaining Hb in patients with anemia of CKD on dialysis in large, community-based dialysis organizations."
05/26/2021 - "Roxadustat represents an innovative and effective agent for the clinical treatment of renal anemia caused by multiple complex factors."
05/01/2023 - "Conclusion Roxadustat is useful for the treatment of anemia in both CKD patients with and without diabetes. "

01/01/2021 - "Safe and Effective Treatment for Anemic Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis on Roxadustat."
01/01/2023 - "This study was conducted to elucidate the safety of roxadustat, an oral medication, in patients with non-dialysis-dependent (NDD) or incident dialysis dialysis-dependent (ID-DD) chronic kidney disease (CKD). "
01/01/2023 - "Lower starting dose of roxadustat in non-dialysis-dependent chronic kidney disease patients with anaemia: a study protocol for a randomised, multicentre, open-label study."
03/25/2022 - "Erratum to: Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: A Phase 3, randomised, open-label, active-controlled study (DOLOMITES)."
01/01/2022 - "Efficacy and Safety of Roxadustat in Patients with Chronic Kidney Disease: An Updated Meta-Analysis of Randomized Controlled Trials including 6,518 Patients."

01/01/2023 - "Here we investigate the protective effects and mechanism of roxadustat (FG-4592), a hypoxia-inducible factor stabilizer, against renal IR injury. "
11/18/2023 - "In addition, we report that application of roxadustat impaired long-term potentiation, but only when applied post-hypoxia. "
10/25/2023 - "Moreover, hypoxia incubation and treatment with Roxadustat restored glycolytic flux. "
01/01/2023 - "According to the results of HE staining, roxadustat could greatly lessen the harm done to rat heart, brain, lung, liver, and kidney tissue as a result of hypoxia. "
01/01/2023 - "To investigate roxadustat's preventive effects on hypoxia damage in the quick ascent to high altitude. "

01/01/2023 - "Meanwhile, FG-4592 improved systolic blood pressure and body temperature drop in septic mice along with alleviated cardiac dysfunction (as shown by the restoration of decreased LVEF and LVFS and increased LDH and CK-MB) and inflammation. "
01/01/2023 - "Several studies suggest that the erythropoiesis effect of roxadustat is less affected by inflammation. "
05/01/2022 - "This study demonstrated that EVs derived from HK2 or HEK293 cells after FG-4592 treatment could alleviate renal tubular injury and inflammation, suggesting a novel therapeutic role of FG-4592/EVs in the treatment of AKI."
02/01/2023 - "Consistent with the in vivo results showing that roxadustat inhibited microglia activation, roxadustat (2, 10, and 20 μM) dose-dependently reduced ROS generation and inflammation in LPS-stimulated BV-2 cells, a mouse microglia cell line, by inhibiting HIF-1α/NF-κB pathway. "
10/01/2020 - "FG-4592 treatment significantly upregulated HIF-1α and HO-1 and strikingly attenuated inflammation in vivo and in vitro. "

01/01/2019 - "EGLN inhibition did not stimulate cancer growth, as treatment with FG-4592 alone, or overexpression of HIF2 within KPC tumors independently improved survival. "
01/01/2020 - "Importantly, FG-4592 displayed anticancer property in cancer cells treated with or without DOX. "
01/01/2019 - "A total of 70 KPC mice with autochthonous pancreatic tumors received oral FG-4592 or vehicle control ± ablative RT to a cumulative 75 Gy administered in 15 daily fractions to a limited tumor field. "
01/01/2019 - "Here, we overcome this fundamental problem of anatomy and biology with the use of the oral EGLN inhibitor FG-4592, which selectively protects the intestinal tract from radiation toxicity without protecting tumors. "
01/01/2023 - "Roxadustat increased Hb in patients with CIA regardless of tumor type and chemotherapy regimen. "